 Dopamine
"Dopamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.
| Descriptor ID |
D004298
|
| MeSH Number(s) |
D02.092.211.215.311.342 D02.092.311.342
|
| Concept/Terms |
Dopamine- Dopamine
- Hydroxytyramine
- 3,4-Dihydroxyphenethylamine
- 3,4 Dihydroxyphenethylamine
- 4-(2-Aminoethyl)-1,2-benzenediol
|
Below are MeSH descriptors whose meaning is more general than "Dopamine".
Below are MeSH descriptors whose meaning is more specific than "Dopamine".
This graph shows the total number of publications written about "Dopamine" by people in UAMS Profiles by year, and whether "Dopamine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 2 | 1 | 3 | | 2023 | 0 | 3 | 3 | | 2022 | 0 | 2 | 2 | | 2021 | 1 | 1 | 2 | | 2020 | 0 | 1 | 1 | | 2019 | 0 | 3 | 3 | | 2018 | 2 | 2 | 4 | | 2017 | 2 | 2 | 4 | | 2016 | 1 | 3 | 4 | | 2015 | 4 | 3 | 7 | | 2014 | 1 | 3 | 4 | | 2013 | 3 | 5 | 8 | | 2012 | 0 | 3 | 3 | | 2011 | 3 | 3 | 6 | | 2010 | 7 | 3 | 10 | | 2009 | 2 | 4 | 6 | | 2008 | 4 | 2 | 6 | | 2007 | 6 | 4 | 10 | | 2006 | 4 | 3 | 7 | | 2005 | 2 | 7 | 9 | | 2004 | 3 | 2 | 5 | | 2003 | 1 | 7 | 8 | | 2002 | 2 | 2 | 4 | | 2001 | 0 | 1 | 1 | | 2000 | 1 | 1 | 2 | | 1997 | 0 | 1 | 1 | | 1996 | 2 | 2 | 4 | | 1993 | 1 | 2 | 3 | | 1992 | 1 | 0 | 1 | | 1991 | 1 | 3 | 4 | | 1990 | 0 | 1 | 1 | | 1989 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dopamine" by people in Profiles over the past ten years.
-
Cai W, Young CB, Yuan R, Lee B, Ryman S, Kim J, Yang L, Levine TF, Henderson VW, Poston KL, Menon V. Subthalamic nucleus-language network connectivity predicts dopaminergic modulation of speech function in Parkinson's disease. Proc Natl Acad Sci U S A. 2024 May 28; 121(22):e2316149121.
-
Chandler CM, Nickell JR, George Wilson A, Culver JP, Crooks PA, Bardo MT, Dwoskin LP. Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats. Biochem Pharmacol. 2024 10; 228:116189.
-
Hersey M, Mereu M, Jones CS, Bartole MK, Chen AY, Cao J, Hiranita T, Chun LE, Lopez JP, Katz JL, Newman AH, Tanda G. Dual DAT and sigma receptor inhibitors attenuate cocaine effects on nucleus accumbens dopamine dynamics in rats. Eur J Neurosci. 2024 May; 59(10):2436-2449.
-
Gupta HV, Lenka A, Dhamija RK, Fasano A. A video-atlas of levodopa-induced dyskinesia in Parkinson's disease: terminology matters. Neurol Sci. 2024 Apr; 45(4):1389-1397.
-
Alkharisi B, Dostzada K, Kaur H, Kumar M, Wei JY, Azhar G. The Importance of Dopamine Deficiency Evaluation in Non-Alzheimer Disease Dementias. Am J Case Rep. 2023 Apr 05; 24:e938344.
-
Zhang X, Berridge MS, Apana SM, Slikker W, Paule MG, Talpos J. Discontinuation of methylphenidate after long-term exposure in nonhuman primates. Neurotoxicol Teratol. 2023 May-Jun; 97:107173.
-
Levy RA, Reiter PD, Spear M, Santana A, Silveira L, Cox S, Mourani PM, Maddux AB. Peripheral Vasoactive Administration in Critically Ill Children With Shock: A Single-Center Retrospective Cohort Study. Pediatr Crit Care Med. 2022 08 01; 23(8):618-625.
-
Syeda HB, Glover A, Pillai L, Kemp AS, Spencer H, Lotia M, Larson-Prior LJ, Virmani T. Amplitude setting and dopamine response of finger tapping and gait are related in Parkinson's disease. Sci Rep. 2022 03 09; 12(1):4180.
-
Zhang X, Talpos J, Berridge MS, Apana SM, Slikker W, Wang C, Paule MG. MicroPET/CT assessment of neurochemical effects in the brain after long-term methylphenidate treatment in nonhuman primates. Neurotoxicol Teratol. 2021 Sep-Oct; 87:107017.
-
Elton A, Faulkner ML, Robinson DL, Boettiger CA. Acute depletion of dopamine precursors in the human brain: effects on functional connectivity and alcohol attentional bias. Neuropsychopharmacology. 2021 07; 46(8):1421-1431.
-
Mereu M, Hiranita T, Jordan CJ, Chun LE, Lopez JP, Coggiano MA, Quarterman JC, Bi GH, Keighron JD, Xi ZX, Newman AH, Katz JL, Tanda G. Modafinil potentiates cocaine self-administration by a dopamine-independent mechanism: possible involvement of gap junctions. Neuropsychopharmacology. 2020 08; 45(9):1518-1526.
-
Ikram H, Tasneem S, Perveen S, Haleem DJ. Neurochemical and behavioral effects of midazolam: A dose related study. Pak J Pharm Sci. 2020 Jan; 33(1):85-93.
-
Hyatt WS, Berquist MD, Chitre NM, Russell LN, Rice KC, Murnane KS, Fantegrossi WE. Repeated administration of synthetic cathinone 3,4-methylenedioxypyrovalerone persistently increases impulsive choice in rats. Behav Pharmacol. 2019 10; 30(7):555-565.
-
Lee NR, Zheng G, Leggas M, Janganati V, Nickell JR, Crooks PA, Bardo MT, Dwoskin LP. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine. J Pharmacol Exp Ther. 2019 11; 371(2):526-543.
-
Lee JY, Tuazon JP, Ehrhart J, Sanberg PR, Borlongan CV. Gutting the brain of inflammation: A key role of gut microbiome in human umbilical cord blood plasma therapy in Parkinson's disease model. J Cell Mol Med. 2019 08; 23(8):5466-5474.
-
Kaiser RH, Treadway MT, Wooten DW, Kumar P, Goer F, Murray L, Beltzer M, Pechtel P, Whitton A, Cohen AL, Alpert NM, El Fakhri G, Normandin MD, Pizzagalli DA. Frontostriatal and Dopamine Markers of Individual Differences in Reinforcement Learning: A Multi-modal Investigation. Cereb Cortex. 2018 12 01; 28(12):4281-4290.
-
Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A. Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J Pharmacol Exp Ther. 2018 08; 366(2):367-376.
-
Lee NR, Zheng G, Crooks PA, Bardo MT, Dwoskin LP. New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders. AAPS J. 2018 02 09; 20(2):29.
-
Gupta P, Rettiganti M, Wilcox A, Vuong-Dac MA, Gossett JM, Imamura M, Chakraborty A. An Empirically Derived Pediatric Cardiac Inotrope Score Associated With Pediatric Heart Surgery. Semin Thorac Cardiovasc Surg. 2018; 30(1):62-68.
-
Fantegrossi WE, Wilson CD, Berquist MD. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug Metab Rev. 2018 Feb; 50(1):65-73.
-
Hankosky ER, Joolakanti SR, Nickell JR, Janganati V, Dwoskin LP, Crooks PA. Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [3H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2017 12 15; 27(24):5467-5472.
-
Naylor JE, Hiranita T, Matazel KS, Zhang X, Paule MG, Goodwin AK. Positron emission tomography (PET) imaging of nicotine-induced dopamine release in squirrel monkeys using [18F]Fallypride. Drug Alcohol Depend. 2017 10 01; 179:254-259.
-
Berquist MD, Baker LE. Characterization of the discriminative stimulus effects of 3,4-methylenedioxypyrovalerone in male Sprague-Dawley rats. Behav Pharmacol. 2017 08; 28(5):394-400.
-
Lantz SM, Rosas-Hernandez H, Cuevas E, Robinson B, Rice KC, Fantegrossi WE, Imam SZ, Paule MG, Ali SF. Monoaminergic toxicity induced by cathinone phthalimide: An in vitro study. Neurosci Lett. 2017 Aug 10; 655:76-81.
-
Nickell JR, Siripurapu KB, Horton DB, Zheng G, Crooks PA, Dwoskin LP. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. Eur J Pharmacol. 2017 Jan 15; 795:143-149.
-
Tanda G, Mereu M, Hiranita T, Quarterman JC, Coggiano M, Katz JL. Lack of Specific Involvement of (+)-Naloxone and (+)-Naltrexone on the Reinforcing and Neurochemical Effects of Cocaine and Opioids. Neuropsychopharmacology. 2016 10; 41(11):2772-81.
-
Katz JL, Hong WC, Hiranita T, Su TP. A role for sigma receptors in stimulant self-administration and addiction. Behav Pharmacol. 2016 Apr; 27(2-3 Spec Issue):100-15.
-
Freyberg Z, Sonders MS, Aguilar JI, Hiranita T, Karam CS, Flores J, Pizzo AB, Zhang Y, Farino ZJ, Chen A, Martin CA, Kopajtic TA, Fei H, Hu G, Lin YY, Mosharov EV, McCabe BD, Freyberg R, Wimalasena K, Hsin LW, Sames D, Krantz DE, Katz JL, Sulzer D, Javitch JA. Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain. Nat Commun. 2016 Feb 16; 7:10652.
-
Saunders JC, Young LM, Mahood RA, Jackson MP, Revill CH, Foster RJ, Smith DA, Ashcroft AE, Brockwell DJ, Radford SE. An in vivo platform for identifying inhibitors of protein aggregation. Nat Chem Biol. 2016 Feb; 12(2):94-101.
-
Gonz?lez CR, Gonz?lez B, Matzkin ME, Mu?iz JA, Cadet JL, Garcia-Rill E, Urbano FJ, Vitullo AD, Bisagno V. Psychostimulant-Induced Testicular Toxicity in Mice: Evidence of Cocaine and Caffeine Effects on the Local Dopaminergic System. PLoS One. 2015; 10(11):e0142713.
-
Salvatore MF, Terrebonne J, Fields V, Nodurft D, Runfalo C, Latimer B, Ingram DK. Initiation of calorie restriction in middle-aged male rats attenuates aging-related motoric decline and bradykinesia without increased striatal dopamine. Neurobiol Aging. 2016 Jan; 37:192-207.
-
Beckmann JS, Meyer AC, Pivavarchyk M, Horton DB, Zheng G, Smith AM, Wooters TE, McIntosh JM, Crooks PA, Bardo MT, Dwoskin LP. r-bPiDI, an a6?2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement. Neurochem Res. 2015 Oct; 40(10):2121-30.
-
MacKillop J, Gray JC, Bidwell LC, Bickel WK, Sheffer CE, McGeary JE. Genetic influences on delay discounting in smokers: examination of a priori candidates and exploration of dopamine-related haplotypes. Psychopharmacology (Berl). 2015 Oct; 232(20):3731-9.
-
Rios DR, Kaiser JR. Reply: To PMID 25641242. J Pediatr. 2015 Aug; 167(2):499.
-
Ding D, Nickell JR, Dwoskin LP, Crooks PA. Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2015 Jul 01; 25(13):2613-6.
-
Rios DR, Kaiser JR. Vasopressin versus dopamine for treatment of hypotension in extremely low birth weight infants: a randomized, blinded pilot study. J Pediatr. 2015 Apr; 166(4):850-5.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|